In the landscape of metabolic disorder treatments, glucagon-like peptide-1 (GLP-1) agonists have emerged as a significant class of therapeutic agents, offering a multifaceted approach in managing conditions such as type 2 diabetes mellitus (T2DM) and obesity1–4. This evidence concerns the gene GLP1R and Other metabolic disease.